Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Topotecan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 known ✓ | P11387 | 19/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 1.00 |
| ▸ | CASP1 | P29466 | 3/20 | 1.00 |
| ▸ | CASP7 | P55210 | 3/20 | 1.00 |
| ▸ | HBB | P68871 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | USP2 | O75604 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | BRCA1 | P38398 | 2/20 | 1.00 |
| ▸ | KEAP1 | Q14145 | 2/20 | 1.00 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | SLC22A2 | O15244 | 1/20 | 1.00 |
| ▸ | TOP2A | P11388 | 1/20 | 1.00 |
| ▸ | TOP2B | Q02880 | 1/20 | 1.00 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Topotecan SCHEMBL3836 | 1.00 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL31517322 | 1.00 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL29350221 | 1.00 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL30712226 | 1.00 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL14577671 | 1.00 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL9971346 | 1.00 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL3927536 | 1.00 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL29726458 | 1.00 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL10278 | 0.99 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL418714 | 0.99 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103289461-B | Camptothecin analogues is as the application of anti-fouling agent | XIAMEN UNIVERSITY (CN) | 2016-05-04 | — | — | CN | claimed |
| CN-1582934-A | Nano micro granules, their preparation and medicinal uses of campotothecin derivative | WANG ANXUN (CN) | 2005-02-23 | — | — | CN | claimed |
| US-20260091021-A1 | COMBINATION THERAPIES COMPRISING PANOBINOSTAT FOR THE TREATMENT OF CHOLANGIOCARCINOMA | SEALD AS (NO) | 2026-04-02 | — | — | US | disclosed |
| EP-4349337-A1 | ANTI-TUMOR AGENT | FUJIFILM Corporation (JP) | 2024-04-10 | — | — | EP | disclosed |
| EP-4349338-A1 | TREATMENT AGENT | FUJIFILM Corporation (JP) | 2024-04-10 | — | — | EP | disclosed |
| US-20240099975-A1 | ANTI-TUMOR AGENT | FUJIFILM CORPORATION (JP) | 2024-03-28 | — | — | US | disclosed |
| US-20230174660-A1 | USE OF A MULTIMERIC ANTI-DR5 BINDING MOLECULE IN COMBINATION WITH A CANCER THERAPY FOR TREATING CANCER | IGM BIOSCIENCES, INC. | 2023-06-08 | — | — | US | disclosed |
| EP-4149553-A1 | USE OF A MULTIMERIC ANTI-DR5 BINDING MOLECULE IN COMBINATION WITH A CANCER THERAPY FOR TREATING CANCER | IGM Biosciences Inc. (US) | 2023-03-22 | — | — | EP | disclosed |
| CN-115697419-A | Use of multimeric anti-DR 5 binding molecules in combination with cancer therapy to treat cancer | IGM生物科学股份有限公司 | 2023-02-03 | — | — | CN | disclosed |
| WO-2022204184-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| US-20220281904-A1 | A PRODRUG PLATFORM USEFUL TO DELIVER AMINES, AMIDES AND PHENOLS | Changchun Changcheng Pharmaceutical Technology Co., LTD (CN) | 2022-09-08 | — | — | US | disclosed |
| CN-1913897-A | Novel compound, corresponding compositions, preparation and/or treatment methods | SMITHKLINE BEECHAM CORP (US) | 2007-02-14 | — | — | CN | disclosed |
| US-7175830-B2 | Imaging of drug accumulation as a guide to antitumor therapy | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICES (US) | 2007-02-13 | — | — | US | disclosed |
| US-7175830-B2 | Imaging of drug accumulation as a guide to antitumor therapy | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICES (US) | 2007-02-13 | — | — | US | disclosed |
| CN-1764663-A | Method for preparing topotecan from 10-hydroxy-4-(S)-camptothecine | COUNCIL SCIENT IND RES (IN) | 2006-04-26 | — | — | CN | disclosed |
| CN-1245977-C | Liposomal antineoplastic drugs and uses thereof | INEX PHARMACEUTICALS CORP (CA) | 2006-03-22 | — | — | CN | disclosed |
| CN-1198616-C | Oral formulations for anti-tumor compounds | PHARMACIA ITALIA SPA (IT) | 2005-04-27 | — | — | CN | disclosed |
| CN-1582934-A | Nano micro granules, their preparation and medicinal uses of campotothecin derivative | WANG ANXUN (CN) | 2005-02-23 | — | — | CN | disclosed |
| CN-1382050-A | Oral formulations for anti-tumor compounds | PHARMACIA ITALIA SPA (IT) | 2002-11-27 | — | — | CN | disclosed |
| WO-1994005672-A1 | PROCESS FOR PREPARING CERTAIN PYRROLO[3,4- b]QUINOLINES, CERTAIN 1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-b]QUINOLIN-3,14(4H,12H)-DIONES, AND CERTAIN 8-METHYL-7-(OXOPROPYL)-INDOLIZINO[1,2-b]QUINOLIN-9(11H)-ONES | SMITHKLINE BEECHAM CORPORATION (US) | 1994-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174660-A1 | USE OF A MULTIMERIC ANTI-DR5 BINDING MOLECULE IN COMBINATION WITH A CANCER THERAPY FOR TREATING CANCER | MCL1, BID, BAD | TOP1 18/4885MEN1 913/4885KMT2A 1327/4885 |
| US-20220281904-A1 | A PRODRUG PLATFORM USEFUL TO DELIVER AMINES, AMIDES AND PHENOLS | GOT1, PAM, GLS2 | TOP1 769/4885MEN1 2752/4885KMT2A 952/4885 |
| US-20260091021-A1 | COMBINATION THERAPIES COMPRISING PANOBINOSTAT FOR THE TREATMENT OF CHOLANGIOCARCINOMA | PLK1, BID, ABCB1 | TOP1 138/4885MEN1 3191/4885KMT2A 595/4885 |
| US-20240099975-A1 | ANTI-TUMOR AGENT | SGMS2, SGMS1, PHOSPHO1 | TOP1 35/4885MEN1 281/4885KMT2A 810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.